Hepatic ADMA/PRMT1 axis regulation is associated with NO-dependent endothelial dysfunction in MASH
Justine Lallement, Sébastian BottiD, Hrag Esfahani, Kristian SerafimoviD, Maxence Henderson, Zoé Benoit, Laurent Dumas, Sultan Al‐SiyabiiD, Olivier FéroniD, Isabelle Anne LeclercqiD, Chantal DessyiD
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a severe form of fatty liver disease and a recognized cardiovascular risk factor, yet the mechanisms linking hepatic pathology to vascular dysfunction remain poorly understood. We aimed to investigate whether MASH impairs endothelial function via nitric oxide (NO)-dependent mechanisms and to identify potential liver-derived mediators involved in this process. Endothelial function was assessed in two murine MASH models, Foz mice fed a high-fat diet and C57BL/6JRj mice fed a western diet with fructose, by using wire myography, while blood pressure was monitored via telemetry. NO pathway was further investigated through eNOS expression and activation and Hb-NO measurements. ADMA metabolism was analyzed in both liver tissue and plasma by LC-MS and gene expressions. Additionally, bovine aortic endothelial cells (BAECs) were treated with mouse plasma to measure the circulating factors effects on eNOS activation and the role of oxidative stress. Both models exhibited impaired NO-dependent vasorelaxation without evidence of atherosclerosis. In Foz mice, this impairment was associated with reduced eNOS expression and activation. Surprisingly, plasma Hb-NO levels did not reflect vascular NO deficiency, likely due to elevated hepatic iNOS expression. In both models, hepatic and plasma ADMA levels were increased, concomitant with hepatic upregulation of Prmt1. BAECs exposed to plasma from MASH mice showed reduced eNOS activation independent of oxidative stress. Our findings reveal that MASH is consistently associated with NO-dependent endothelial dysfunction, with ADMA emerging as a key liver-derived mediator. The PRMT1/ADMA/NO axis may represent a mechanistic link between liver pathology and vascular impairment, positioning ADMA as a potential biomarker and therapeutic target for cardiovascular risk associated with MASH. HighlightsO_LIMASH is associated with impaired NO-dependent endothelial function in two distinct MASH models. C_LIO_LICirculating factors disrupt the NOS/NO pathway independently of oxidative stress C_LIO_LIReduced plasma Hb-NO levels do not accurately reflect NO-dependent endothelial dysfunction in a context of MASH. C_LIO_LIElevated plasma and hepatic ADMA levels associated with hepatic prmt1 upregulation are consistently observed in both MASH models. C_LIO_LIThe PRMT1/ADMA/NO axis emerges as a key liver-mediated mechanism driving endothelial dysfunction in MASH C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Increased endothelium activation and leakage do not promote diastolic dysfunction in mice fed with a high fat diet and treated with L-NAME
L. Cornuault, P. Mora, … M.-A. Renault·bioRxiv·Feb 8, 2023
- Mechanistic Links Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction in a Mouse Model
Niveen Rweished, Yair Rokach, … Rabea Asleh·bioRxiv·Nov 2, 2025
- A Translational Model of MASLD-Associated HFpEF Defines Mitochondrial Dysfunction and Cardiac Plasticity During Disease Progression and Regression
Souradipta Ganguly, Betul Beyza Gunes, … Debanjan Dhar·MetabolismPeer-reviewed·Jun 22, 2026
- When the liver is in poor condition, so is the heart - cardiac remodelling in MASH mouse models
Sébastian Bott, Justine Lallement, … Isabelle Anne Leclercq·Clinical SciencePeer-reviewed·Aug 29, 2024
- Lysine methyltransferase SET7 links cardiometabolic risk to endothelial dysfunction by dysregulating mRNA splicing and eNOS-CaM interaction
Julia Sánchez-Ceinos, Georgios Filis, … Francesco Cosentino·bioRxiv·Aug 4, 2026
- Ketogenesis protects against MASLD-MASH progression through mechanisms that extend beyond overall fat oxidation rate
Eric D. Queathem, David B. Stagg, … Peter A. Crawford·Journal of Clinical InvestigationPeer-reviewed·Apr 24, 2025